Stock-Based Compensation (Tables)
|
9 Months Ended |
Jun. 30, 2026 |
|---|
| Share-Based Payment Arrangement [Abstract] |
|
| Schedule of Awards Outstanding |
The following table presents a summary of awards outstanding attributable to Arrowhead Pharmaceuticals, Inc.: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | June 30, 2026 | | | 2013 Plan | | 2021 Plan | | Inducement Awards | | Total | | Granted and outstanding awards: | | | | | | | | | | Options | | 480,277 | | | 22,965 | | | 326,934 | | | 830,176 | | | Restricted stock units | | 1,100,000 | | | 4,011,324 | | | 683,330 | | | 5,794,654 | | | Total | | 1,580,277 | | | 4,034,289 | | | 1,010,264 | | | 6,624,830 | |
|
| Schedule of Stock-Based Compensation Expenses |
The following table summarizes stock-based compensation expenses included in operating expenses attributable to Arrowhead Pharmaceuticals, Inc.: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Nine Months Ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | | (in thousands) | | Research and development | $ | 8,187 | | | $ | 6,898 | | | $ | 23,003 | | | $ | 21,008 | | | Selling, general and administrative | 6,787 | | | 5,095 | | | 28,129 | | | 20,242 | | | Total | $ | 14,974 | | | $ | 11,993 | | | $ | 51,132 | | | $ | 41,250 | |
|
| Schedule of Stock Option Activity |
The following table presents a summary of the stock option activity for the nine months ended June 30, 2026: | | | | | | | | | | | | | | | | | | | | | | | | | Shares | | Weighted-
Average
Exercise
Price
Per Share | | Weighted-
Average
Remaining
Contractual
Term (Years) | | Aggregate
Intrinsic
Value | Outstanding at September 30, 2025 | 1,407,035 | | $ | 28.90 | | | | | | | Granted | — | | — | | | | | | | Cancelled or expired | — | | — | | | | | | | Exercised | (576,859) | | 22.88 | | | | | | Outstanding at June 30, 2026 | 830,176 | | $ | 32.97 | | | 3.0 | | $ | 40,293,644 | | Exercisable at June 30, 2026 | 830,176 | | $ | 32.97 | | | 3.0 | | $ | 40,293,644 | |
|
| Schedule of Share Activity Related to RSUs |
The following table summarizes the activity of the Company’s RSUs: | | | | | | | | | | | | | Number of
RSUs | | Weighted-
Average
Grant
Date
Fair Value
Per Share | Outstanding at September 30, 2025 | 5,810,351 | | $ | 36.97 | | | Granted | 2,049,141 | | 66.42 | | | Vested | (1,794,793) | | 41.69 | | | Forfeited | (270,045) | | 31.55 | | Outstanding at June 30, 2026 | 5,794,654 | | $ | 49.69 | |
|